Experts Assess Carnegie Commission's Impact On U.S. Science Policy

The Carnegie Commission on Science, Technology, and Government, created in 1988 by the Carnegie Corporation of New York as a five-year-long effort to assess the way science is taken into account in the formulation of United States policy, ends its tenure June 30. The commission, its advisory council, and its 15 committees and task forces have included "the elite of the science policy community in the country," in the words of Rep. George E. Brown, Jr. (D-Calif.)--among them three Nobel-ists (

Written byBarbara Spector
| 13 min read

Register for free to listen to this article
Listen with Speechify
0:00
13:00
Share

The Carnegie Commission on Science, Technology, and Government, created in 1988 by the Carnegie Corporation of New York as a five-year-long effort to assess the way science is taken into account in the formulation of United States policy, ends its tenure June 30. The commission, its advisory council, and its 15 committees and task forces have included "the elite of the science policy community in the country," in the words of Rep. George E. Brown, Jr. (D-Calif.)--among them three Nobel-ists (Rockefeller University geneticist Joshua Lederberg, University of Chicago physicist Leon M. Lederman, and Massachusetts Institute of Technology economist Robert M. Solow) and two former U.S. presidents (Jimmy Carter and Gerald R. Ford).

In assessing the success of the commission, outside observers as well as those associated with the group point to several of its recommendations that were implemented by the Bush and Clinton administrations and others that have earned a ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies